Intelligence · Clinical Development
Pipeline search results
Programs matching “chemotherapy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 127 pipeline programs matching "chemotherapy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
2 cycles induction chemotherapy
The First People's Hospital of Lianyungang
Locally Advanced Nasopharyngeal Carcinoma
1 trial -
20170770
Amgen
Chemotherapy-induced Thrombocytopenia in Adult subjects with Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
1 trial -
2215-CL-0201
Astellas Pharma GmbH
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
ADAURA - D5164C00001
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
APF530
Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
1 trial -
APHP230864
Pari Pharma GmbH
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
1 trial -
AT148006
Wuhan Createrna Science and Technology Co., Ltd
Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)
1 trial -
Adjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Total Neoadjuvant Treatment
1 trial -
Balugrastim
Teva Pharma GmbH
Chemotherapy-induced Neutropenia
1 trial -
CO-338-087
pharmaand GmbH
Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer
1 trial -
Capox chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Cancer
1 trial -
Chemotherapy
United Therapeutics Europe Ltd
Transitional Cell Carcinoma of Ureter
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Endometrial Cancer
1 trial -
Chemotherapy
International Peace Maternity and Child Health Hospital
Non Small Cell Lung Cancer
1 trial -
Chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
Chemotherapy + avelumab followed by avelumab + talazoparib
Pfizer
Ovarian Cancer
1 trial -
Chemotherapy drug
Chinese PLA General Hospital
Gastric Cancer
1 trial -
Concurrent chemotherapy
Disc Medicine
Uterine Cervical Neoplasms
1 trial -
D9268C00001
AstraZeneca AB
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"
1 trial -
DANUBE/D419BC00001
AstraZeneca AB
Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.
1 trial -
DLY201619
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer Stage IIIA
1 trial -
Durvalumab + SoC chemotherapy
AstraZeneca
Carcinoma, Non-Small-Cell Lung
1 trial -
HIPEC with neoadjuvant chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.